Drugs / JL18008
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07443228 | May 2026 → Dec 2029 expected | HIV infectious disease | Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07629310 | Jun 2024 → Aug 2025 | HIV infectious disease | Jecho Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07579741 | Apr 2026 → Jul 2027 expected | HIV infectious disease | Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JL18008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07629310 ↗ |
| Known as | Recombinant Human Interleukin-7 | “Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders” NCT07443228 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-7 (JL18008)” NCT07443228 ↗ |
| Route | Intramuscular | “JL18008 i.m. 1 μg/kg” NCT07443228 ↗ |